Literature DB >> 23232943

Skin testing for Beta-lactam antibiotics: impact of the availability of a major determinant.

Fatima S Khan1, Michael E Weiss.   

Abstract

Beta-lactam antibiotics are very effective agents for a variety of infections. In patients with beta-lactam allergy, these drugs are withheld due to fear of subsequent allergic reactions. Therefore, increasing their exposure to broad spectrum antibiotics, which are more costly, have greater side effects, and increase the risk of developing resistant organisms. Up to 90 % of patients with a proposed beta-lactam sensitivity can tolerate beta lactam agents after appropriate evaluation. Skin testing to beta-lactam agents is the gold standard in evaluating patients with type I, immediate hypersensitivity reactions. The robust negative predictive value of this test has yet to be surpassed by any other testing modality currently available.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23232943     DOI: 10.1007/s11882-012-0323-y

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  48 in total

1.  Side-chain specific beta-lactam allergy.

Authors:  N F Adkinson
Journal:  Clin Exp Allergy       Date:  1990-09       Impact factor: 5.018

2.  Penicillin skin testing: a 20-year study at the West Los Angeles Veterans Affairs Medical Center.

Authors:  William B Klaustermeyer; Vinay C Gowda
Journal:  Mil Med       Date:  2005-08       Impact factor: 1.437

3.  Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge.

Authors:  M E Pichichero; D M Pichichero
Journal:  J Pediatr       Date:  1998-01       Impact factor: 4.406

4.  Skin testing with penicilloate and penilloate prepared by an improved method: amoxicillin oral challenge in patients with negative skin test responses to penicillin reagents.

Authors:  E Macy; P K Richter; R Falkoff; R Zeiger
Journal:  J Allergy Clin Immunol       Date:  1997-11       Impact factor: 10.793

5.  Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin.

Authors:  R Naclerio; E A Mizrahi; N F Adkinson
Journal:  J Allergy Clin Immunol       Date:  1983-03       Impact factor: 10.793

6.  Immunological cross-reactivities of cephalothin and its related compounds with benzylpenicillin (penicillin G).

Authors:  K Shibata; T Atsumi; Y Horiuchi; K Mashimo
Journal:  Nature       Date:  1966-10-22       Impact factor: 49.962

7.  Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy.

Authors:  William A Prescott; Daryl D DePestel; Jeffrey J Ellis; Randolph E Regal
Journal:  Clin Infect Dis       Date:  2004-03-26       Impact factor: 9.079

8.  Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin.

Authors:  R K Chandra; S A Joglekar; E Tomas
Journal:  Arch Dis Child       Date:  1980-11       Impact factor: 3.791

9.  Urticaria caused by sensitization to aztreonam.

Authors:  R de la Fuente Prieto; A Armentia Medina; P Sanchez Palla; J M Diez Perez; M E Sanchis Merino; A Fernandez Garcia
Journal:  Allergy       Date:  1993-11       Impact factor: 13.146

10.  Diagnosis of penicillin allergy by skin testing: the Manitoba experience.

Authors:  R J Warrington; F E Simons; H W Ho; B A Gorski
Journal:  Can Med Assoc J       Date:  1978-04-08       Impact factor: 8.262

View more
  2 in total

Review 1.  Practical Management of Patients with a History of Immediate Hypersensitivity to Common non-Beta-Lactam Drugs.

Authors:  Eric Macy
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

2.  Disparities in rate, triggers, and management in pediatric and adult cases of suspected drug-induced anaphylaxis in Canada.

Authors:  Sofianne Gabrielli; Ann E Clarke; Harley Eisman; Judy Morris; Lawrence Joseph; Sebastien La Vieille; Peter Small; Rodrick Lim; Paul Enarson; Michal Zelcer; Edmond S Chan; Chris Mill; Moshe Ben-Shoshan
Journal:  Immun Inflamm Dis       Date:  2017-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.